BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to dateAnnounced SOLARA-2, the single-arm pivotal Phase 2 portion of the SOLARA trial, designed with registrational intent to e…